Shangpin China's high-end Website construction On February 27, 2017, Shangpin China signed a contract with Beijing Union Rock Biotechnology Co., Ltd.
Beijing Xiehe Rock Biotechnology Co., Ltd., formerly known as Beijing Xiehe Rock Biotechnology Research and Development Center (hereinafter referred to as Xiehe Rock), was founded in 1996 and reorganized and transformed in 2013. It is a national high-tech enterprise, focusing on biotechnology, focusing on early warning, diagnosis Research and development of treatment related products and establishment of production system. The company has a complete system of basic research, medical transformation, scientific and technological achievements, standard production, quality control and market promotion.
Cardiovascular and cerebrovascular diseases have become the biggest killer threatening human health. They are characterized by rapid onset and high mortality. Xiehe Lock focuses on early warning, diagnosis and treatment of cardiovascular and cerebrovascular diseases, focusing on "scientific and technological innovation, early warning, precision medicine, and health management". The R&D center of the company, relying on the Chinese Association of Research Hospitals, Peking University Medical Department, and clinical bases of research hospitals at home and abroad, independently develops and actively expands the market for diagnosis and treatment of cardiovascular and cerebrovascular diseases while maintaining the market share in the field of neonatal screening. In May 2015, the company and LUMINEX officially signed a cooperation agreement on protein chip project in the field of cardio cerebrovascular diseases in Beijing. The purpose is to establish a full range of diagnostic and detection platforms for cardio cerebrovascular diseases, combine different diagnostic markers, and achieve comprehensive and effective diagnosis of cardio cerebrovascular diseases.
At the same time of continuous development in the field of in vitro diagnosis of cardio cerebrovascular diseases, the company cooperated with Peking University Medical Department and Guizhou Taibang Biological Products Co., Ltd. to develop recombinant drugs for human blood for the treatment of cardio cerebrovascular diseases. The company is committed to building a professional R&D, production and operation platform covering the diagnosis and treatment of cardiovascular and cerebrovascular diseases, so as to build an industrial base for cardiovascular and cerebrovascular disease diagnosis and treatment products.
The company has built a Rockyouyou.com Chinese cardiovascular and cerebrovascular health management service platform integrating science education and health services（
Www.luckyouyou. com), covering fitness, elderly care, health care, psychology, public welfare and other sectors, through inclusive education to make the public aware of the importance of cardiovascular and cerebrovascular health management, develop the habit of spontaneous health management, fundamentally prevent and control diseases, and improve the physical and mental health of the public.
Xiehe Rock adheres to the national strategy of scientific and technological innovation and entrepreneurship, focuses on the health management of the health industry, and strives to become a brand enterprise in the biomedical field of "Made in China in 2025".
